Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 11:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,108 matching trials from the live ClinicalTrials.gov search.
Conditions
Human Papillomavirus
Interventions
Novel point-of-care diagnostic test for detecting HPV ("Rice HPV test")
Diagnostic Test
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
21 Years and older · Female only
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Houston, Texas
Conditions
Depressive Disorder, Major
Interventions
No Intervention
Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 74 Years
Enrollment
545 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
18
States / cities
Birmingham, Alabama • Homewood, Alabama • California City, California + 15 more
Completed Phase 2 Interventional Results available

Tocilizumab (TCZ) in New-onset Type 1 Diabetes

NCT02293837
Conditions
Type 1 Diabetes Mellitus, New-onset Type 1 Diabetes Mellitus, T1DM, T1D
Interventions
Tocilizumab (TCZ), Placebo, Standard of Care
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Years to 17 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
17
States / cities
San Francisco, California • Stanford, California • New Haven, Connecticut + 14 more
Conditions
Small Cell Lung Cancer Extensive Stage, Merkel Cell Carcinoma
Interventions
225Ac-SSO110 + SoC, Atezolizumab, Durvalumab, Avelumab, Pembrolizumab, Retifanlimab
Drug
Lead sponsor
Ariceum Therapeutics GmbH
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
6
States / cities
Miami, Florida • Louisville, Kentucky • Glen Burnie, Maryland + 3 more
Active, not recruiting No phase listed Observational Accepts healthy volunteers

REFLECTION: A Clinical Practice Learning Program for Galleri®

NCT05205967
Conditions
Early Detection of Cancer, Cancer
Interventions
MCED, SOC
Other
Lead sponsor
GRAIL, Inc.
Industry
Eligibility
22 Years and older
Enrollment
14,633 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
16
States / cities
Scottsdale, Arizona • Burbank, California • Fullerton, California + 13 more
Conditions
Arthritis, Rheumatoid
Interventions
GSK3196165 (Otilimab), Sarilumab, Placebo to GSK3196165/ Sarilumab, csDMARDs
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
46
States / cities
Mesa, Arizona • Phoenix, Arizona • Sun City, Arizona + 36 more
Conditions
Post Operative Surgical Site Infection
Interventions
Standard of care, Vancomycin and Tobramycin
Drug
Lead sponsor
Major Extremity Trauma Research Consortium
Other
Eligibility
18 Years to 64 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
31
States / cities
Redwood City, California • San Francisco, California • Aurora, Colorado + 25 more
Conditions
HIV Testing
Interventions
Intervention, Enhanced Standard of Care, Traditional Standard of Care
Behavioral
Lead sponsor
City University of New York, School of Public Health
Other
Eligibility
18 Years and older
Enrollment
4,458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
New York, New York
Conditions
Glioblastoma
Interventions
Trans Sodium Crocetinate plus SOC, Standard of Care (SOC)
Drug · Other
Lead sponsor
Diffusion Pharmaceuticals Inc
Industry
Eligibility
18 Years to 70 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
13
States / cities
Irvine, California • Redwood City, California • Santa Monica, California + 10 more
Conditions
Leukemia, High Risk Acute Lymphoblastic Leukemia, High Risk Acute Myeloid Leukemia, Relapse Leukemia, MDS (Myelodysplastic Syndrome), Relapsed Non-Hodgkin Lymphoma, Acquired Aplastic Anemia, Inherited BMF Syndrome, Immunodeficiency, Primary Immune Regulatory Disorder, Hemoglobinopathies, Bone Marrow Failure, Inborn Errors of Metabolism, HLH
Interventions
Phase 1 Dose Level 1, Phase 1 Dose Level 2, Phase 1 Dose Level 3, Phase 2 Maximum Tolerated Dose determined in Phase 1, Phase 2 Established Dose from prior study, NCT03810196
Device
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
1 Month to 25 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Covid19
Interventions
LY3819253, Placebo, Remdesivir, VIR-7831, BRII-196/BRII-198, AZD7442, MP0420, PF-07304814
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
2,753 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
98
States / cities
Tucson, Arizona • Chula Vista, California • Fresno, California + 64 more
Conditions
Pelvic Organ Prolapse
Interventions
Guided IMagery (GIM)
Behavioral
Lead sponsor
Loyola University
Other
Eligibility
21 Years and older · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Maywood, Illinois
Conditions
Diabetic Foot Ulcer, Diabetic Foot, Foot Ulcer Due to Type 2 Diabetes Mellitus, Foot Ulcer, Diabetic, Foot Ulcer
Interventions
Standard of Care, EPIEFFECT, EPIXPRESS
Other
Lead sponsor
MiMedx Group, Inc.
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Monroeville, Pennsylvania
Conditions
Dyspnea, Hypertension, Acute Heart Failure
Interventions
Stage 1: Clevidipine (double-blinded), Stage 1: Placebo (double-blinded), Stage 2: Clevidipine (open-label), Stage 2: Standard of Care (open-label)
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
9
States / cities
Montgomery, Alabama • Tucson, Arizona • St Louis, Missouri + 5 more
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
rituximab, busulfan, carmustine, cyclophosphamide, cytarabine, etoposide, fludarabine phosphate, melphalan, total body irradiation (TBI), anti-thymocyte globulin IV
Biological · Drug · Radiation
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Detroit, Michigan
Conditions
Systematic Lupus Erythematosus, Cutaneous Lupus Erythematosus
Interventions
Enpatoran, Placebo, Standard of care (SoC)
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
14
States / cities
Upland, California • DeBary, Florida • Fort Lauderdale, Florida + 11 more
Conditions
Metastatic Breast Cancer
Interventions
Anakinra plus Standard of Care
Drug
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Postpartum, Hypertension, Hypertensive Disorder of Pregnancy
Interventions
2-Week Home Monitoring, 6-Week Home Monitoring
Diagnostic Test
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older · Female only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Hyperphosphatemia, Anemia, Iron Deficiency, Renal Insufficiency
Interventions
Ferric Citrate 1 gram Oral Tablet, Standard of care phosphate-lowering therapy
Drug
Lead sponsor
USRC Kidney Research
Network
Eligibility
18 Years and older
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
13
States / cities
Anchorage, Alaska • Mesa, Arizona • Pine Bluff, Arkansas + 6 more
Conditions
Head and Neck Carcinoma
Interventions
Best Practice, Counseling, Electroencephalography, Neurofeedback, Questionnaire Administration
Other · Procedure · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Houston, Texas
Conditions
Prostate Carcinoma
Interventions
Targeted Prostate Biopsy, Prostate Imaging Reporting & Data System, Deep Learning Artificial Intelligence, Green Learning Artificial Intelligence, Radical Prostatectomy
Procedure · Diagnostic Test
Lead sponsor
University of Southern California
Other
Eligibility
20 Years and older · Male only
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Completed Phase 4 Interventional Results available

Myositis Interstitial Lung Disease Nintedanib Trial

NCT05799755
Conditions
Myositis Associated Interstitial Lund Disease (MA-ILD)
Interventions
Nintedanib, Placebo, Standard of Care
Drug
Lead sponsor
Rohit Aggarwal, MD
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
10
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Denver, Colorado + 6 more
Conditions
Sickle Cell Disease
Interventions
Voxelotor Oral Tablet
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years to 30 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
2
States / cities
St Louis, Missouri • The Bronx, New York
Completed Phase 2 Interventional Results available

Fostamatinib for Hospitalized Adults With COVID-19

NCT04579393
Conditions
Coronavirus Disease 2019
Interventions
Placebo, fostamatinib
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Bethesda, Maryland • Falls Church, Virginia